SCHEMBL4359559

SCHEMBL4359559

Cc1cccc(C)c1NC(=O)Nc1ccc(O)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 2/20 0.56
IDH1 O75874 2/20 0.55
MAPT P10636 4/20 0.54
GAA P10253 2/20 0.54
NPC1 O15118 5/20 0.52
RAB9A P51151 4/20 0.52
EPHX2 P34913 2/20 0.51
EPHX1 P07099 1/20 0.51
MEN1 O00255 2/20 0.50
TRPV1 Q8NER1 1/20 0.50
CA2 P00918 1/20 0.50
POLB P06746 1/20 0.50
HSD17B10 Q99714 1/20 0.49
IDH2 P48735 1/20 0.48
KCNJ6 P48051 1/20 0.48
KCNJ5 P48544 1/20 0.48
KCNJ3 P48549 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353920 0.85 DHODH (0.60) SMN1; SMN2KMT2AALDH1A1IDH1MAPT
SCHEMBL4360021 0.84 DDX3X (0.66) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL4353772 0.82 KMT2A (0.56) SMN1; SMN2KMT2AALDH1A1IDH1MAPT
SCHEMBL21230469 0.80 IDH1 (0.65) SMN1; SMN2KMT2AALDH1A1IDH1MAPT
SCHEMBL4358566 0.80 MEN1 (0.69) SMN1; SMN2KMT2AMAPTGAANPC1
SCHEMBL4347168 0.79 KMT2A (0.61) SMN1; SMN2KMT2AALDH1A1IDH1MAPT
SCHEMBL7821909 0.79 IDH1 (0.55) SMN1; SMN2KMT2AALDH1A1IDH1TRPV1
SCHEMBL7814404 0.78 KMT2A (0.55) KMT2AALDH1A1IDH1MAPTRAB9A
SCHEMBL11357914 0.78 ALDH1A1 (0.59) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL4345497 0.78 MEN1 (0.74) SMN1; SMN2KMT2AALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885KMT2A 2096/4885ALDH1A1 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.